CHI, Cambridge Healthtech Institute

Conference Menu

Overview

Agenda-Day One

Agenda-Day Two

Download PDF

Register

Hotel & Travel

Press Pass

Request Brochure

Send to a Colleague

PSS Hompage

White Paper Downloads

Pharmacogenomics
and the Evolution
of Healthcare
Mohan V. Bala and Gary Zarkin

Personalized Healthcare 2010
IBM Business Consulting Services

Corporate Sponsor:

Sponsoring Organization:

Lead Sponsoring Publications:

Sponsoring Publications:

Web
Partners:

Overview

The pharmaceutical industry is changing.
Advances in sciences have forced us to redefine our R&D strategies. Targeted Therapeutics and companion diagnostics strategies must balance out the blockbuster medications. As strategists, we need to create new ways to remain competitive and profitable in our changed environment.

If you have responsibility for the strategies of marketing and R&D, you must attend this event to:
• Network and brainstorm with your peers
• Identify what the regulators, physicians and payors are saying about stratified pharmaceuticals
• Watch presentations from the leading diagnostic companies
• Interact with the pharmaceutical leaders in personalized medicine

Distinguished Faculty
Dr. Felix Frueh, Associate Director, Genomics Office of Clinical Pharmacology and Biopharmaceutics, CDER, FDA

Dr. Wayne Rosenkrans, Director of Business Strategy, External Scientific Affairs, AstraZeneca Pharmaceuticals

Dr. Marlene E. Haffner, Director, Office of Orphan Products Development, FDA

Dr. Pamela S. Cohen, Executive Director, Oncology, Novartis

Sharon Terry, President & CEO, Genetic Alliance, and Founding Executive Director, PXE International

Dr. Janet A. Warrington, Vice President, Emerging Markets and Molecular Diagnostics Research and Development, Affymetrix, Inc.

Angus Hastie, Director, Global Marketing and Business Development, Roche Molecular Diagnostics

Douglas E. Onsi, Vice President, Business Development, Genzyme Corporation

Dr. Mark Chang, Partner, Life Science Practice, Strategic Decisions Group

Luis T. Gutierrez, Jr., Corporate Vice President and General Manager, Covance Health Economics and Outcomes Services Inc.

Dr. Michael Caldwell, Principal Investigator, Personalized Medicine Research Project, Surgery, Marshfield Clinic

Dr. Peter Verlander, Associate Director for Strategic Development, Laboratory for Molecular Medicine, Harvard Medical School/Partners Healthcare Center for Genetics and Genomics
Dr. Mohan Bala, Director of Outcome Research, Centocor, Inc.

Michael Stocum, Managing Director, Personalized Medicine Partners and Former Director, Business Development & Alliance Management, Human Biomarker Centers, GlaxoSmithKline R&D

Dr. William Leaf-Herrmann, Partner, Life Science Practice, Strategic Decisions Group

Dr. Edward Abrahams, Executive Director, Personalized Medicine Coalition

Dr. Gurvaneet Randhawa, Senior Service Fellow, Center for Outcomes and Evidence, Agency

for Healthcare Research and Quality

Dr. Melissa Paoloni, DVM, Comparative Oncology Program, National Cancer Institute, National Institutes of Health

John Freshley, President and CEO, Genetics Squared, Inc.

Mr. Kareem Saad, WW Business Segment Executive, IBM Healthcare and Life Sciences

Audrey Goddard, Associate Director, Diagnostics Operations, Genentech, Inc.

Duncan John, Senior Engagement Manager, Life Science Practice, Strategic Decisions Group

Annarie Lyles, Senior Director, Business Development, Medarex

William Crown, Senior Vice President, Economics and Outcomes Research, Ingenix Pharmaceutical Services

Philip Banks, Director, Biostatistical Research and Consulting i3 STATPROBE

Mr. Gregory Hines, President & CEO, TM Bioscience

Facilitated Roundtable Discussions
• Regulatory barriers and incentives to targeted therapies
• Marketing a targeted therapy; what's different?
• The role of targeted therapy in an era of heightened safety concerns
• The Genetic Non-Discrimination Bill and its implications on genetic research

Attend this event to discuss the following:
• The changing pharmaceutical model - from blockbuster to targeted therapeutics
• Competing/profiting with the new strategic model
• The role of diagnostic companies in the new model
• The impact on CRO's and clinical trials
• Pricing strategies - premiums for efficacy
• The economic ramifications of the changing marketplace
• Impact for marketing - new strategies and thought processes
• Internal impact on R&D strategies
• The regulatory role on pharmacogenomic applications
• How payors and providers factor into the equation
• The need for new forecasting and projection strategies that relate to the new model

Who should attend?
The 2nd Annual Targeted Therapeutics Summit is being produced for Vice Presidents, Heads of Departments, Directors and Managers of the following areas:
• Strategic marketing
• Licensing
• Genomics
• Strategic Planning
• Business Development
• Research and Development
• Pharmacogenomics
• Business Affairs
• Regulatory Affairs
• Reimbursement and Pricing
• New Product Planning
• Diagnostics

Call for Sponsors
Showcase your company’s expertise, brand your solutions and develop revenue opportunities with qualified decision-makers by becoming a Sponsor! If you want to discuss sponsoring at this conference, please contact Arnold Wolfson at 781-972-5431, awolfson@healthtech.com